Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) shares are trending upward in pre-market trading. Oramed stock was up 2.76% to $10.05 at the time of last check this morning. During the last trading session, ORMP stock prices closed at $9.78, an increase of 4.60% or $0.43.
Over the course of the day, shares of ORMP stock fluctuated between $9.424 and $9.80. An amount of 0.3 million shares was traded during the session, a decline of 64.71% in contrast to the ORMP’s average session volume of 858.96K shares. ORMP stock has been rising on news its CEO is attending a webinar today to discuss recent developments.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Read More
Webinar details:
It is Oramed Pharmaceuticals that believes oral delivery systems are a viable alternative to the current injection-based delivery systems. ORMP was established in 2006 in the United States and Israel and has developed the first technology for protein oral delivery (POD). In addition, ORMP has identified ORMD-0801 as a potential commercial oral insulin capsule to treat diabetes as their proprietary lead candidate.
A live webinar today will feature Oramed CEO Nadav Kidron. Webinar title is Grand Rounds: A Webinar in Biotech and Specialty Pharma. It will be hosted by James Molloy, Managing Director of Equity Research, Biotechnology, and Specialty Pharmaceuticals at Alliance Global Partners. The webcast will be broadcast online today at 11:00 Eastern.
What is ORMP up to?
Several Phase II clinical trials have been performed by Oramed (ORMP) under its Investigational New Drug application with the U.S. Food and Drug Administration. Furthermore, ORMP is developing an orally available version of GLP-1 called ORMD-0901.